U.S. IVD and LDT for Autoimmune Diseases Market To Reach $4,745.4 Million By 2024: Grand View Research, Inc.

The U.S. IVD for autoimmune diseases market   was valued at USD 4.0 billion in 2015 and is expected to reach a value of USD 4.74 billion by 2024 .The U.S. Laboratory Developed Test (LDT) for autoimmune diseases was valued at USD 830.9 million in 2015. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.


Further Key Findings from the Study Suggest:

  • In 2015, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 14.05% and the LDT for rheumatoid arthritis had a share of 13.2%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share.
  • In 2015, clinical chemistry was the leading segment with a market share of 35.6% in the IVD and 34.1% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share.
  • Some key participants in this field include Becton, Dickinson and Company; Roche Diagnostics; Abbott Laboratories; Bio-Rad Laboratories, Inc.; Danaher Corporation; SQI Diagnostics; Omega Diagnostics Group PLC; ThermoFisher Scientific, Inc.; and some others. The key players focus specially on developing innovative solutions for diagnosis. The laboratories and institutes such as Mayo Medical Laboratories, Oklahoma Medical Research Foundation, and Moleculera Labs also operate in the U.S. in the same domain.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the U.S. IVD and LDT for autoimmune diseases market by application and technology:

U.S. IVD and LDT for Autoimmune Diseases Market: Application Outlook (Market Revenue in USD Billion, 2013 - 2024)

  • Addison’s Disease
  • Ankylosing Spondylitis
  • Alopecia Areata
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Psoriasis
  • Antiphospholipid Antibody Syndrome
  • Diabetes Type 1
  • Crohn’s Disease
  • Ulcerative Colitis
  • Narcolepsy
  • Multiple Sclerosis
  • Uveitis
  • Others
U.S. IVD and LDT for Autoimmune Diseases Market: Technology Outlook (Market Revenue in USD Billion, 2013 - 2024)

  • Immunoassays
  • Clinical Chemistry
  • Hematology
  • Coagulation
  • Microbiology
  • Molecular Diagnostics

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare

For more information: www.grandviewresearch.com

Comments

Popular posts from this blog

The global vein illuminator market is expected to reach USD 358.5 million by 2024, according to a new report published by Grand View Research, Inc. The vein illuminator market is anticipated to witness a lucrative growth during the period 2016 to 2024. The factors contributing towards the growth of the market are the growing aging population and the efforts channelized towards improving patient satisfaction. Additionally, factors, such as the demand for technologically advanced medical equipment and the rising research and practical applications are expected to be opportunistic for the industry growth. However, the prevalence of traditional methods owing to the high costs of the vein illuminator devices is likely to hinder the growth of the market in the near future. The vein illuminator market is segmented on the basis of technology, application, end-user, and region. Based on technology, the market is further categorized into transillumination, infrared technology, and ultrasound. The near-infrared illumination technology is estimated to be the largest shareholder due to its ability to penetrate deep into the tissue, which makes it possible to visualize the vessels clearly. On the basis of application, the market is segmented into intravenous access and blood draw. The end-user segment comprises hospitals, rehabilitation facilities, blood donation camps, and academic institutions. The market for hospitals is expected to grow rapidly during the forecast period due to a surge in the demand for technologically advanced medical equipment. The market is also categorized into North America, Europe, Asia Pacific, MEA, and Latin America. Browse full research report on global Vein Illuminator Market: http://www.grandviewresearch.com/industry-analysis/vein-illuminator-market Further key findings from the study suggest: • In terms of market share, the North America vein illuminator market is expected to hold majority of the share in 2016. Factors resulting in the growth of this industry are the steady preference for highly-advanced medical devices by hospitals as well as the presence of several medical device manufacturing companies in the region. • The infrared illumination technology is estimated to lead the industry due to its deep penetration capability into thick tissues tohighlight the presence of vessels with increased clarity. Based on application, the segment for intravenous access is estimated to be the largest shareholder, followed by the blood draw segment. • The vein illuminator industry comprises several local as well as global players. Some prominent players in this industry include Accuvein, Inc., Christie Medical Holdings, Inc., Infrared Imaging Systems, Inc., Translite, LLC, and Venoscope, LLC,among others. In order to hold a major share in the industry, the companies are adopting both organic as well as inorganic strategies. The major strategies adopted by the companies are new product development, mergers, collaborations, partnerships, geographical expansions, and acquisitions. • The companies are also focusing on research and development activities in order to enhance their product portfolio. For instance, in September 2015, Accuvein, Inc., declared its 26th patent, which was issued by the United States Patent and Trademark office for their vein visualization system. Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices Grand View Research has segmented the vein illuminator market on the basis of technology, application, and end-user application: Vein Illuminator Technology Outlook (Revenue, USD Million, 2013 - 2024) • Transillumination • Infrared technology • Others Vein Illuminator Application Outlook (Revenue, USD Million, 2013 - 2024) • Intravenous access • Blood draw • Others Vein Illuminator End-user Outlook (Revenue, USD Million, 2013 - 2024) • Hospitals • Blood donation camps • Academic institutions • Others Vein Illuminator Regional Outlook (Revenue, USD Million, 2013 - 2024) • North America • Europe • Asia Pacific • Latin America • MEA Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-vein-illuminator-market About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc For more information: www.grandviewresearch.com

Hyaluronic Acid Market Is Likely To Be Influenced By The Increase In Obesity Till 2024: Grand View Research, Inc.

Protein Purification & Isolation Market Is Predicted To Grow Swiftly Due To Increased Research In The Fields Of Biotechnology & Pharmaceuticals Till 2025: Grand View Research, Inc.